The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Bispecific antibodies under investigation for the treatment of frontline and R/R follicular lymphoma
In this video, Reid Merryman, MD, Dana-Farber Cancer Institute, Boston, MA, briefly highlights the bispecific antibodies under investigation for the treatment of follicular lymphoma (FL), both in the frontline and relapsed/refractory (R/R) setting. Agents such as epcoritamab, mosunetuzumab, and odronextamab are being explored both as monotherapy and as combination therapy approaches. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So on the theme of bispecific antibodies, there are numerous ongoing Phase III trials in the first line setting and in the second line plus setting. Trials for epcoritamab, mosunetuzumab, and odronextamab that are testing different strategies and just different combination partners. So we’re seeing combination with lenalidomide as the primary strategy in the relapsed/refractory setting, and then in the frontline setting combinations with lenalidomide, chemotherapy, rituximab, or monotherapy...
So on the theme of bispecific antibodies, there are numerous ongoing Phase III trials in the first line setting and in the second line plus setting. Trials for epcoritamab, mosunetuzumab, and odronextamab that are testing different strategies and just different combination partners. So we’re seeing combination with lenalidomide as the primary strategy in the relapsed/refractory setting, and then in the frontline setting combinations with lenalidomide, chemotherapy, rituximab, or monotherapy. So I think in the next three to five years, we’ll see practice changing data for frontline and relapsed/refractory FL, and I’m excited about the ability to move these very active drugs into our standard of care regimen for patients with follicular lymphoma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Advisory board: Genmab, Adaptive Biotechnologies, Bristol Myers Squibb, Abbvie, Inteillia, Epizyme, Ipsen, KITE; Consulting: Alphasights, DG Medicine; Honararia: Genmab, Abbvie; Institutional research funding: Merck, Bristol Myers Squibb, Genmab, Genente.
